Cell Membrane Lipid-Extracted Nanoliposomes for Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy methods face challenges such as limited interstitial drug transport, off-target drug effects, and formulation instability, despite advancements in liposome technology for tumor targeting.
Innovation Solution
Development of cell membrane lipid-extracted nanoliposomes (CLENs) that closely resemble the composition of target cell membranes, incorporating chemotherapeutic agents like doxorubicin, and additional agents like cholesterol and PEG to enhance targeting and delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional nanoliposomes are used for drug delivery, then formulation stability is improved, but selective targeting capability deteriorates
Solution Approach 1:
The patent extracts lipid components specifically from cancer cell membranes to create nanoliposomes with tumor-specific targeting capabilities. This extraction process isolates the membrane lipids that naturally recognize and bind to cancer cells, thereby resolving the contradiction between using conventional stable formulations and achieving selective targeting.
Solution Approach 2:
The patent applies local quality by incorporating specific cancer cell-derived lipid components into the nanoliposome structure. These localized lipid regions provide the selective targeting function while the overall nanoliposome formulation maintains its structural stability, thus resolving the contradiction between stability and targeting capability.
2Duration of action of moving object
If PEG is included in nanoliposomes to extend circulation, then circulation time is improved, but tumor penetration capability deteriorates
Solution Approach 1:
The patent changes the lipid composition parameters by incorporating cancer cell membrane-derived lipids that provide active targeting functionality. This compositional change allows the nanoliposomes to maintain extended circulation (when PEG is included) while simultaneously gaining enhanced tumor penetration capability through the cancer-specific lipid components.
Solution Approach 2:
The patent creates composite nanoliposome structures that combine PEG for extended circulation with cancer cell membrane-derived lipids for tumor penetration. This composite approach integrates materials with complementary properties, resolving the contradiction between circulation time and penetration capability.
3Ease of manufacture
If non-specific lipid extracts are used, then manufacturing simplicity is improved, but cellular uptake efficiency deteriorates
Solution Approach 1:
The patent extracts specific lipid components from cancer cell membranes to create nanoliposomes with tumor-specific targeting capabilities. This extraction process isolates the membrane lipids that naturally recognize and bind to cancer cells, thereby resolving the contradiction between using conventional stable formulations and achieving selective targeting.
Solution Approach 2:
The patent applies local quality by incorporating specific cancer cell-derived lipid components into the nanoliposome structure. These localized lipid regions provide the selective targeting function while the overall nanoliposome formulation maintains its structural stability, thus resolving the contradiction between stability and targeting capability.
Data Source
AI summary
Nanoliposome compositions and methods of making the same for selective targeting, image analysis and therapy (e.g., cancer therapy) are provided. In some aspects, the nanoliposomes comprise membrane material derived from cells (e.g., tumor cells) in order to selectively target agents (e.g., chemotherapeutic agents) to cancer cells. Membranes used to generate the nanoliposomes provided herein may be derived from cells in vivo, ex vivo, or in vitro. The disclosure also provides pharmaceutical compositions comprising nanoliposomes and methods of treatment by administering the same.